U.S. Markets open in 6 hrs 20 mins

Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
87.310.00 (0.00%)
As of 5:36PM CEST. Market open.
People also watch
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
Previous Close87.31
Open87.80
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range87.11 - 87.99
52 Week Range62.50 - 92.97
Volume1,653,151
Avg. Volume2,311,399
Market Cap109.9B
BetaN/A
PE Ratio (TTM)24.04
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis
    Investor's Business Daily2 days ago

    Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis

    Regeneron and Sanofi's rheumatoid arthritis drug is 15%-30% cheaper than rival drugs from Amgen, AbbVie and Roche, an analyst said Tuesday.

  • American City Business Journals2 days ago

    ​Sanofi Genzyme takes on world’s top-selling drugs with new approval

    With Monday’s announcement that U.S. regulators have approved a drug for rheumatoid arthritis developed by Sanofi Genzyme and Regeneron Pharmaceuticals, the two drugmakers revealed a tried-and-true strategy to take on the world’s number one and number three best-selling drugs, which also happen to be for that same disease: give it a lower price. Cambridge-based Sanofi Genzyme (SNY) and Tarrytown, N.Y.-based Regeneron (REGN) will market their new drug, which has the generic name of sarilumab, under the name of Kevzara. Rheumatoid arthritis affects about 1.3 million Americans, mostly women, and Kevzara is approved for those with moderate to severe forms of the disease that aren’t well treated by other drugs.

  • Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
    Zacks3 days ago

    Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

    Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.